April 2026

Testing New Therapies for Ovarian Cancer in a 3D Model

A new 3D peritoneal matrix model recreates the tumour microenvironment of metastatic ovarian cancer, enabling more physiologically relevant studies and the preclinical evaluation of both conventional and cell-based therapies.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Register
Already a user? Login

Author

Christiane Helgestad Gjerde

MD, PhD, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway

Author

Katrin Kleinmanns

PhD, M.Sc., postdoctoral researcher, Department of obstetrics and Gynecology, Haukeland University Hospital, Department of Clinical Science, Centre for Cancer Biomarkers CCBIO, University of Bergen, Norway

Author

Emmet McCormack

PhD, head, Pharmaceutics, professor, pharmacy, PI, Centre for Cancer Biomarkers CCBIO, associated PI, K.G. Jebsen Centre for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, senior researcher, Department of Medicine, Hematology Section, Haukeland University Hospital associated PI, Centre for Cancer Cell Reprogramming (CanCell), University of Oslo, Norway

Author

Line Bjørge

MD, PhD, MBA, medical director, gynecological oncology, Haukeland University Hospital, professor, obstetrics and gynecology, Department of Clinical Science, co-director, Centre for Cancer Biomarkers CCBIO, University of Bergen, Norway

Testing New Therapies for Ovarian Cancer in a 3D Model

Get access

Related